ClinicalTrials.gg
TerminatedNCT03306420Updated Feb 6, 2020Results posted

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

A Phase 1 interventional study of M4112 in Metastatic or Locally Advanced Unresectable Solid Tumors, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-06.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state of M4112.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Merck KGaA, Darmstadt, Germany.

Enrollment
15th of 17
15 · median 141
Started
2017
the only one that year
Phase 1
11 of 21
none open now
Registered
18th of 21
by date

Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 11 in phase 1, and was the 18th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 892 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

None of the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Neoplasm Metastasis, anywhere →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with MS201408-0005C or MS201408-0005B (Part IB, Part IC).

03

Conditions studied

  • Metastatic or Locally Advanced Unresectable Solid Tumors

Browse trials for

Keywords

  • MS201408-0005A
  • MS201408-0005B
  • MS201408-0005C
  • First-in-Human
  • Advanced solid tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with or cytologically proven advanced or solid for whom no effective standard therapy exists or has failed or subjects who are intolerant to established therapy known to provide clinical benefit for their condition (dose escalation cohorts; Part I).
  • An performance status (ECOG PS) of 0 to 1 at screening and adequate hematological, renal and hepatic function as defined by protocol specified criteria.
  • Other protocol defined inclusion criteria could apply.

Exclusion criteria

Exclusion Criteria:

  • Intolerance to therapy as defined by the occurrence of an adverse drug reaction requiring drug discontinuation (dose escalation cohorts), concurrent anticancer treatment or agents.
  • Prior organ transplantation including stem cell transplantation, (except those meeting certain protocol specified criteria which are acceptable), significant acute or chronic infections, a history of cardiovascular/cerebrovascular disease.
  • Current significant cardiac conduction abnormalities and hypokalemia as specified in the protocol.
  • Warfarin or other Vitamin K antagonists treatment, strong inhibitors or inducers of cytochrome P450 (CYP)3A4, and drugs with a narrow therapeutic index, which are predominantly metabolized by and drugs known to have a high risk to prolong as per label.
  • Pregnancy or lactation.
  • Severe reactions to monoclonal antibodies, known hypersensitivity to the medicinal products or to one or more of the , diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and within 28 days prior to study entry.
  • Pneumonitis and history of pneumonitis.
  • Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Part IA Dose Escalation: M4112 100 mg

    Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

    Drug: M4112

  • Experimental
    Part IA Dose Escalation: M4112 200 mg

    Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

    Drug: M4112

  • Experimental
    Part IA Dose Escalation: M4112 400 mg

    Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

    Drug: M4112

  • Experimental
    Part IA Dose Escalation: M4112 600 mg

    Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

    Drug: M4112

  • Experimental
    Part IA Dose Escalation: M4112 800 mg

    Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

    Drug: M4112

Interventions

  • DrugM4112

    All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).

06

What researchers measure

Primary outcomes

  1. Part 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03

    DLTs was assessed as per NCI CTCAE v 4.03. DLT defined as any Grade greater than or equal (\>=) 3 nonhematological AE or Immune-related adverse event (irAE) assessed by Investigator or Sponsor during first Cycle (first 28 days) of study treatment. Asymptomatic Grade \>= 3 lipase or amylase elevation not associated with clinical manifestations of pancreatitis. Any TEAE observed in subsequent cycle. Any Grade 4 neutropenia of \>= 5 days duration, Grade \>= 3 febrile neutropenia, Grade 3 hemoglobin decrease despite blood transfusion or erythroid growth factor. Grade 4 hemoglobin decrease assessed as related to study drug. Any Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding. Any Grade \>= 3 clinical signs and symptoms related to increased QTc.

    Time frame: Cycle 1 (Each Cycle is of 28 days)

  2. Part 1A Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Who Experienced a Treatment Related Adverse Events (TRAE) According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03

    An adverse event (AE) was defined as any untoward medical occurrence in participant which does not necessarily have casual relationship with treatment was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. Treatment related AE was defined as having a "Possible" or "Related" relationship to study treatment, as assessed by the Investigator.

    Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months

  3. Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    The laboratory measurements included hematology, biochemistry and hormonal tests. Number of participants with any clinically significant abnormalities in laboratory measurements were reported. Clinical significance was determined by the investigator.

    Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months

  4. Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital signs assessment included blood pressure, pulse rate and body temperature. Number of Participants with any clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.

    Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months

  5. Part 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 1

    ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 4, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. Number of participants with on-treatment shift in ECOG PS Score from 0 to 1 were reported.

    Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months

  6. Part 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities

    A complete physical examination (including, general appearance, skin, pulmonary, cardiovascular, gastrointestinal, external genitourinary only as medically relevant, lymphatic, neurologic and musculoskeletal systems, head/neck, extremities, eyes, ears, nose, throat, and cognitive status) was performed. Number of participants with clinical significant change from baseline in physical examination abnormalities were reported. Clinical significance was determined by the investigator.

    Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months

Secondary outcomes

  1. Part 1A Dose Escalation: Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post Dose AUC(0-8h) of M4112

    Area under the drug concentration-time curve from 0 to 8 h post dosing for M4112. AUC0-8 was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  2. Part 1A Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of M4112

    Pharmacokinetic PK parameter Cmax was obtained directly from the plasma concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  3. Part 1A Dose Escalation: Time to Reach Maximum Plasma Concentration (Tmax) of M4112

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  4. Part 1A Dose Escalation: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (AUC0-8/Dose) of M4112

    Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 8 h postdose divided by dose.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  5. Part 1A Dose Escalation: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4112

    Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  6. Part 1A Dose Escalation: Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (Racc[AUC0-8h]) of M4112

    Accumulation ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 hours After Administration (Racc\[AUC0-8h\]) of M4112 was reported. Racc(AUC0-8h) calculated as AUC0-8h, on Cycle 1 Day 15 divided by AUC0-8h on Cycle 1 Day 1.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  7. Part IA Dose Escalation: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4112

    Accumulation ratio for Cmax was calculated as Cmax, Cycle 1 Day 15 divided by Cmax, Cycle 1 Day 1.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)

  8. Part 1A Dose Escalation: Pre-dose Observed Plasma Concentration (Cpre) of M4112

    Maximum pre-dose observed plasma concentration was reported.

    Time frame: Pre-dose on Days 8, 15 (Cycle 1) and Day 1 (Cycle 2) (Each Cycle is 28 days)

  9. Part 1A Dose Escalation: Dose Normalized Pre-dose Observed Plasma Concentration (Cpre/Dose) of M4112

    Dose normalized pre-dose observed plasma concentration (Cpre/dose) of M4112 was reported.

    Time frame: Pre-dose on Days 8, 15 (Cycle 1) and Day 1 (Cycle 2) (Each Cycle is 28 days)

  10. Part 1A Dose Escalation: Slope of Concentration-QTc (cQTc) Regression of M4112

    Time-matched, replicate ECGs and PK samples collected in the dose-escalation phase and planned to analyze QTC response using slope analysis of exposure/response.

    Time frame: Baseline up to safety follow-up visit, assessed up to 15.4 months

  11. Part 1A Dose Escalation: Number of Participants With Best Overall Response (BOR)

    BOR was determined according to Response Evaluation Criteria in Solid Tumors version1.1(RECIST 1.1).Best response obtained among all tumor assessment visits after the date of first study drug administration until documented disease progression. BOR rate is defined as the number of participants with BOR was either confirmed complete response (CR) partial response (PR), stable disease (SD) and progressive disease (PD) relative to the number of participants belonging to the study of interest. CR:Disappearance of all target lesions; PR:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; PD:At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.

    Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months

  12. Part 1A Dose Escalation: Duration of Response

    Duration of response defined as time from first documentation of objective response complete response (CR) or partial response (PR) whichever is first recorded) to date of first documentation of objective progression of disease or death due to any cause whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of longest diameter (SLD) of all lesions.

    Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months

  13. Part 1A Dose Escalation: Disease Control Rate

    Disease control was defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD. CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. Percentage of participants with disease control were reported.

    Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months

  14. Part 1A Dose Escalation: Time to Tumor Response

    Tumor response was defined as the presence of at least 1 confirmed complete response (CR) or confirmed partial response (PR) as judged by RECIST version 1.1. CR was defined for target lesions (TLs) as the disappearance of all lesions, and for non-target lesions (NTLs) as the disappearance of all non-target non-measurable lesions and/or normalization of serum levels of tumor markers. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs.

    Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months

  15. Part 1A Dose Escalation: Progression Free Survival Time (PFS)

    Progression free survival time defined as time from start date to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.

    Time frame: From first dose of study drug administration until PD, assessed up to 15.4 months

07

Results

Posted Feb 6, 2020
Limitations and caveats
Part IB and Part IC for this study were never initiated as the study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state at a range of tested dose levels of M4112.

Participant flow

First Participant First Visit: 03-Oct-2017 Last Participant Last Visit: 14-Jan-2019.

Participant flow — Overall Study
MilestonePart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Started33333
Completed33333
Not completed00000

Outcome measures

PrimaryPart 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03

DLTs was assessed as per NCI CTCAE v 4.03. DLT defined as any Grade greater than or equal (\>=) 3 nonhematological AE or Immune-related adverse event (irAE) assessed by Investigator or Sponsor during first Cycle (first 28 days) of study treatment. Asymptomatic Grade \>= 3 lipase or amylase elevation not associated with clinical manifestations of pancreatitis. Any TEAE observed in subsequent cycle. Any Grade 4 neutropenia of \>= 5 days duration, Grade \>= 3 febrile neutropenia, Grade 3 hemoglobin decrease despite blood transfusion or erythroid growth factor. Grade 4 hemoglobin decrease assessed as related to study drug. Any Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding. Any Grade \>= 3 clinical signs and symptoms related to increased QTc.

Time frame:
Cycle 1 (Each Cycle is of 28 days)
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) as Per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0300001
PrimaryPart 1A Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Who Experienced a Treatment Related Adverse Events (TRAE) According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03

An adverse event (AE) was defined as any untoward medical occurrence in participant which does not necessarily have casual relationship with treatment was any unfavorable and unintended sign(including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event(SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. Treatment related AE was defined as having a "Possible" or "Related" relationship to study treatment, as assessed by the Investigator.

Time frame:
Baseline up to safety follow-up visit, assessed up to 15.4 months
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Who Experienced a Treatment Related Adverse Events (TRAE) According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Any TEAE33333
Any Related TEAE32133
PrimaryPart 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

The laboratory measurements included hematology, biochemistry and hormonal tests. Number of participants with any clinically significant abnormalities in laboratory measurements were reported. Clinical significance was determined by the investigator.

Time frame:
Baseline up to safety follow-up visit, assessed up to 15.4 months
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters10001
PrimaryPart 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs assessment included blood pressure, pulse rate and body temperature. Number of Participants with any clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.

Time frame:
Baseline up to safety follow-up visit, assessed up to 15.4 months
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Number of Participants With Clinically Significant Abnormalities in Vital Signs20111
PrimaryPart 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 1

ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 4, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. Number of participants with on-treatment shift in ECOG PS Score from 0 to 1 were reported.

Time frame:
Baseline up to safety follow-up visit, assessed up to 15.4 months
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 1
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Number of Participants With On-Treatment Shift in Eastern Cooperative Oncology Performance Status (ECOG PS) Score From 0 to 110101
PrimaryPart 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities

A complete physical examination (including, general appearance, skin, pulmonary, cardiovascular, gastrointestinal, external genitourinary only as medically relevant, lymphatic, neurologic and musculoskeletal systems, head/neck, extremities, eyes, ears, nose, throat, and cognitive status) was performed. Number of participants with clinical significant change from baseline in physical examination abnormalities were reported. Clinical significance was determined by the investigator.

Time frame:
Baseline up to safety follow-up visit, assessed up to 15.4 months
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Abnormalities00000
SecondaryPart 1A Dose Escalation: Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post Dose AUC(0-8h) of M4112

Area under the drug concentration-time curve from 0 to 8 h post dosing for M4112. AUC0-8 was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Part 1A Dose Escalation: Area Under the Plasma Concentration Curve From Time Zero to 8 Hours Post Dose AUC(0-8h) of M4112
nanogram*hour per milliliter (ng*h/mL)Part 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 13550 ± 14.48740 ± 13.627700 ± 21.450400 ± 7.714600 ± 85.1
Cycle 1 Day 154790 ± 25.47580 ± 11.531500 ± 28.859500 ± 12.7NA ± NA
SecondaryPart 1A Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of M4112

Pharmacokinetic PK parameter Cmax was obtained directly from the plasma concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part 1A Dose Escalation: Maximum Observed Plasma Concentration (Cmax) of M4112
nanogram per milliliter (ng/mL)Part 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 1806 ± 9.92110 ± 13.67670 ± 39.611700 ± 24.62770 ± 83.6
Cycle 1 Day 15975 ± 34.91720 ± 20.56560 ± 27.412100 ± 2.2NA ± NA
SecondaryPart 1A Dose Escalation: Time to Reach Maximum Plasma Concentration (Tmax) of M4112

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Median · Hours
Part 1A Dose Escalation: Time to Reach Maximum Plasma Concentration (Tmax) of M4112
HoursPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 11.08 (1.08 to 2.12)2.10 (2.07 to 3.08)1.08 (1.07 to 1.08)1.00 (0.97 to 1.07)2.08 (2.07 to 4.12)
Cycle 1 Day 153.08 (2.12 to 4.13)2.10 (1.00 to 6.08)1.08 (0.50 to 3.00)1.03 (0.93 to 2.17)NA (2.00 to 2.00)
SecondaryPart 1A Dose Escalation: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (AUC0-8/Dose) of M4112

Dose normalized was calculated as area under the plasma concentration-time curve from time zero to 8 h postdose divided by dose.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Geometric mean · ng*h/mL/mg
Part 1A Dose Escalation: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (AUC0-8/Dose) of M4112
ng*h/mL/mgPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 135.5 ± 14.443.7 ± 13.669.1 ± 21.484.0 ± 7.718.2 ± 85.1
Cycle 1 Day 1547.9 ± 25.437.9 ± 11.578.8 ± 28.899.2 ± 12.7NA ± NA
SecondaryPart 1A Dose Escalation: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4112

Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Geometric mean · ng/mL/mg
Part 1A Dose Escalation: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4112
ng/mL/mgPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 18.06 ± 9.910.5 ± 13.619.2 ± 39.619.6 ± 24.63.47 ± 83.6
Cycle 1 Day 159.75 ± 34.98.58 ± 20.516.4 ± 27.420.2 ± 2.2NA ± NA
SecondaryPart 1A Dose Escalation: Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (Racc[AUC0-8h]) of M4112

Accumulation ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 hours After Administration (Racc\[AUC0-8h\]) of M4112 was reported. Racc(AUC0-8h) calculated as AUC0-8h, on Cycle 1 Day 15 divided by AUC0-8h on Cycle 1 Day 1.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Geometric mean · Ratio
Part 1A Dose Escalation: Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (Racc[AUC0-8h]) of M4112
RatioPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hour Post-dose (Racc[AUC0-8h]) of M41121.35 ± 11.40.868 ± 15.31.14 ± 50.11.18 ± 9.4NA ± NA
SecondaryPart IA Dose Escalation: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4112

Accumulation ratio for Cmax was calculated as Cmax, Cycle 1 Day 15 divided by Cmax, Cycle 1 Day 1.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 h post-dose on Day 1 and 15 of Cycle 1 (Each Cycle is for 28 days)
Reported as:
Geometric mean · Ratio
Part IA Dose Escalation: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4112
RatioPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part IA Dose Escalation: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M41121.21 ± 24.80.815 ± 7.00.856 ± 66.81.03 ± 23.0NA ± NA
SecondaryPart 1A Dose Escalation: Pre-dose Observed Plasma Concentration (Cpre) of M4112

Maximum pre-dose observed plasma concentration was reported.

Time frame:
Pre-dose on Days 8, 15 (Cycle 1) and Day 1 (Cycle 2) (Each Cycle is 28 days)
Reported as:
Geometric mean · ng/mL
Part 1A Dose Escalation: Pre-dose Observed Plasma Concentration (Cpre) of M4112
ng/mLPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 8156 ± 58.296.5 ± 85.01240 ± 51.64410 ± 54.55200 ± 105.4
Cycle 1 Day 15221 ± 20.5199 ± 53.91630 ± 45.73380 ± 42.4NA ± NA
Cycle 2 Day 1128 ± 67.7NA ± NA957 ± 72.1NA ± NANA ± NA
SecondaryPart 1A Dose Escalation: Dose Normalized Pre-dose Observed Plasma Concentration (Cpre/Dose) of M4112

Dose normalized pre-dose observed plasma concentration (Cpre/dose) of M4112 was reported.

Time frame:
Pre-dose on Days 8, 15 (Cycle 1) and Day 1 (Cycle 2) (Each Cycle is 28 days)
Reported as:
Geometric mean · ng/mL/mg
Part 1A Dose Escalation: Dose Normalized Pre-dose Observed Plasma Concentration (Cpre/Dose) of M4112
ng/mL/mgPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Cycle 1 Day 81.56 ± 58.20.482 ± 85.03.11 ± 51.67.35 ± 54.56.50 ± 105.4
Cycle 1 Day 152.21 ± 20.50.997 ± 53.94.08 ± 45.75.63 ± 42.4NA ± NA
Cycle 2 Day 11.28 ± 67.7NA ± NA2.39 ± 72.1NA ± NANA ± NA
SecondaryPart 1A Dose Escalation: Slope of Concentration-QTc (cQTc) Regression of M4112

Time-matched, replicate ECGs and PK samples collected in the dose-escalation phase and planned to analyze QTC response using slope analysis of exposure/response.

Time frame:
Baseline up to safety follow-up visit, assessed up to 15.4 months

No measurements were reported for this outcome.

SecondaryPart 1A Dose Escalation: Number of Participants With Best Overall Response (BOR)

BOR was determined according to Response Evaluation Criteria in Solid Tumors version1.1(RECIST 1.1).Best response obtained among all tumor assessment visits after the date of first study drug administration until documented disease progression. BOR rate is defined as the number of participants with BOR was either confirmed complete response (CR) partial response (PR), stable disease (SD) and progressive disease (PD) relative to the number of participants belonging to the study of interest. CR:Disappearance of all target lesions; PR:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; PD:At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.

Time frame:
From first dose of study drug administration until PD, assessed up to 15.4 months
Reported as:
Count of participants · Participants
Part 1A Dose Escalation: Number of Participants With Best Overall Response (BOR)
ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Complete Response00000
Partial Response00000
Stable Disease23310
Progressive Disease10022
SecondaryPart 1A Dose Escalation: Duration of Response

Duration of response defined as time from first documentation of objective response complete response (CR) or partial response (PR) whichever is first recorded) to date of first documentation of objective progression of disease or death due to any cause whichever occurs first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of longest diameter (SLD) of all lesions.

Time frame:
From first dose of study drug administration until PD, assessed up to 15.4 months

No measurements were reported for this outcome.

SecondaryPart 1A Dose Escalation: Disease Control Rate

Disease control was defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD. CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. Percentage of participants with disease control were reported.

Time frame:
From first dose of study drug administration until PD, assessed up to 15.4 months
Reported as:
Number · Percentage of Participants
Part 1A Dose Escalation: Disease Control Rate
Percentage of ParticipantsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Disease Control Rate66.7 (9.4 to 99.2)100 (29.2 to 100.0)100 (29.2 to 100.0)33.3 (0.8 to 90.6)0.0 (0.0 to 70.8)
SecondaryPart 1A Dose Escalation: Time to Tumor Response

Tumor response was defined as the presence of at least 1 confirmed complete response (CR) or confirmed partial response (PR) as judged by RECIST version 1.1. CR was defined for target lesions (TLs) as the disappearance of all lesions, and for non-target lesions (NTLs) as the disappearance of all non-target non-measurable lesions and/or normalization of serum levels of tumor markers. PR was defined for TLs as at least a 30 percent (%) decrease from baseline (BL) in the sum of longest diameter (SLD) of TLs.

Time frame:
From first dose of study drug administration until PD, assessed up to 15.4 months

No measurements were reported for this outcome.

SecondaryPart 1A Dose Escalation: Progression Free Survival Time (PFS)

Progression free survival time defined as time from start date to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.

Time frame:
From first dose of study drug administration until PD, assessed up to 15.4 months
Reported as:
Median · Months
Part 1A Dose Escalation: Progression Free Survival Time (PFS)
MonthsPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
Part 1A Dose Escalation: Progression Free Survival Time (PFS)3.7 (1.9 to 8.1)5.5 (3.9 to 5.5)NA (2.1 to 10.2)1.8 (1.1 to 3.7)1.2 (0.0 to 1.2)

Adverse events

Collected over Baseline up to safety follow-up visit, assessed up to 15.4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A Dose Escalation: M4112 100 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part 1A Dose Escalation: M4112 200 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part 1A Dose Escalation: M4112 400 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1A Dose Escalation: M4112 600 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part 1A Dose Escalation: M4112 800 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
AscitesGastrointestinal disorders0/30/30/31/30/3
Disease progressionGeneral disorders0/30/31/30/30/3
Dermatitis allergicSkin and subcutaneous tissue disorders0/30/30/30/31/3
Most frequent other events
Showing 10 of 69
Most frequent other events
EventPart 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mg
DiarrhoeaGastrointestinal disorders0/31/30/32/30/3
DyspepsiaGastrointestinal disorders2/30/30/30/30/3
VomitingGastrointestinal disorders2/31/30/31/30/3
FatigueGeneral disorders2/30/31/31/31/3
Aspartate aminotransferase increasedInvestigations0/30/30/30/32/3
Lipase increasedInvestigations0/31/30/32/30/3
AnaemiaBlood and lymphatic system disorders0/30/31/30/30/3
Anaemia of malignant diseaseBlood and lymphatic system disorders0/30/31/31/30/3
ThrombocytopeniaBlood and lymphatic system disorders0/30/30/31/30/3
PalpitationsCardiac disorders0/30/31/30/30/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mgTotal
Mean60.7 ± 14.8454.7 ± 8.3343.0 ± 9.5467.7 ± 7.5162.3 ± 14.8457.7 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mgTotal
Female2323313
Male101002
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mgTotal
Hispanic or Latino101103
Not Hispanic or Latino2322312
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1A Dose Escalation: M4112 100 mgPart 1A Dose Escalation: M4112 200 mgPart 1A Dose Escalation: M4112 400 mgPart 1A Dose Escalation: M4112 600 mgPart 1A Dose Escalation: M4112 800 mgTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American101013
White2323212
More than one race000000
Unknown or Not Reported000000
08

Study locations

3 sites
  • Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • University of TX M.D. Anderson Cancer Center-Investigational Cancer Therapeutics Partner
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics (START)
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Naing A, Eder JP, Piha-Paul SA, Gimmi C, Hussey E, Zhang S, Hildebrand V, Hosagrahara V, Habermehl C, Moisan J, Papadopoulos KP. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. J Immunother Cancer. 2020 Aug;8(2):e000870. doi: 10.1136/jitc-2020-000870. PubMed 32843490 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jan 2019, 15 months.

Results were first posted in Feb 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2017
First posted
Oct 11, 2017
StartActual
Oct 3, 2017
Primary completionActual
Jan 14, 2019
CompletionActual
Jan 14, 2019
Results first posted
Feb 6, 2020
Last update
Feb 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03306420
Responsible party
Sponsor
First posted
Oct 11, 2017
Start date
Oct 3, 2017
Primary completion
Jan 14, 2019
Completion
Jan 14, 2019
Results posted
Feb 6, 2020
Last update
Feb 6, 2020

Study contacts

Medical Responsible
study director · EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion